Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 6/20 | 0.36 |
| ▸ | HTR1B | P28222 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1051875 | 0.76 | HTR1D (0.38) | HTR1DHTR1BRAB9ASMN1; SMN2HTR1A | |
| SCHEMBL1050754 | 0.75 | KDM4E (0.30) | — | |
| SCHEMBL3270876 | 0.70 | REN (0.42) | — | |
| SCHEMBL1050660 | 0.69 | MTNR1A (0.35) | HTR1DHTR1BRAB9AHTR1AMTNR1B | |
| SCHEMBL3770009 | 0.69 | HTR1D (0.36) | HTR1DHTR1BSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL3770011 | 0.66 | HTR1D (0.36) | HTR1DHTR1BSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL1049807 | 0.66 | HTR1D (0.35) | HTR1DHTR1BRAB9AHTR1AMTNR1B | |
| SCHEMBL78477 | 0.65 | HTR1D (0.66) | HTR1DHTR1BHTR1AHTR2AMPO | |
| SCHEMBL4533872 | 0.64 | HTR1D (0.31) | HTR1DHTR1B | |
| SCHEMBL3772837 | 0.64 | CAPN1 (0.34) | HTR1DHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | HTR1D 698/4885HTR1B 517/4885RAB9A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.